Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
N Z Med J
June 2006
Outcome Management Services, Paremata, Wellington.
Pressure to fund Herceptin (trastuzumab) for use in early-stage breast cancer is a welcome development for those patients who may benefit. However such a decision would have major implications since the health gains made by trastuzumab come at a very high cost (when compared to health gains achieved by other drugs currently funded on PHARMAC's schedule). The budget for trastuzumab (estimated to be NZ30m dollars/annum but this is currently being negotiated) will be funded from district health board (DHB) budgets, which will impact other patients unless DHB budgets are appropriately increased.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!